Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Peptide and tumor reactivity of gp100154–162 specific CD8+ T cell clones *

From: Use of high throughput qPCR screening to rapidly clone low frequency tumour specific T-cells from peripheral blood for adoptive immunotherapy

  Peptide Reactivity   Tumor Reactivity
gp100154 (M) HIV (M) A2+/gp100+ A2+/gp100+ A2-/gp100+ A2-/gp100-  
  10-6 10-7 10-8 10-9 10-10 10-11 10-12 10-6 Mel 526 Mel 624 Mel 888 Hep 3B Media
Patient 2 clone 7105 6606 5102 2555 187 < 10 < 10 < 10 2724 5743 < 10 < 10 < 10
Patient 5 clone 12067 11274 5323 1210 244 < 10 < 10 < 10 5114 7425 < 10 < 10 < 10
Patient 7 clone 33349 29191 26858 18575 687 220 < 10 < 10 3975 8434 < 10 < 10 < 10
  1. * Specific reactivity of cloned T cells was evaluated by tumor or peptide-specific stimulation. 1e5 cloned T cells were cocultured overnight with an equal number of melanoma tumor cells or T2 cells pulsed with either 1 μM irrelevant HIV peptide or titered concentrations of gp100:154–162 peptide, and assessed for IFN-g (pg/ml) production by standard ELISA
  2. Values 100 pg/ml and twice background are bolded and underlined.